Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis

English version České info

In a large cross-sectional study done in India, Sunil Solomon and colleagues report on respondent-driven sampling for identification of HIV and HCV infections.

Vyšlo v časopise: Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis. PLoS Med 14(11): e32767. doi:10.1371/journal.pmed.1002460
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002460

Souhrn

In a large cross-sectional study done in India, Sunil Solomon and colleagues report on respondent-driven sampling for identification of HIV and HCV infections.

Zdroje

1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57. doi: 10.1016/S0140-6736(08)61697-9 19038438

2. Alter HJ, Liang TJ. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med. 2012;156(4):317–8. doi: 10.7326/0003-4819-156-4-201202210-00014 22351718

3. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2014 [cited 2014 Oct 14]. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/90-90-90_en.pdf.

4. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–9. doi: 10.1001/jama.300.1.51 18594040

5. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol. 2017; 67(2):263–71. doi: 10.1016/j.jhep.2017.03.039 28412293

6. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607. doi: 10.1056/NEJMoa1512610 26571066

7. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17. doi: 10.1056/NEJMoa1512612 26575258

8. Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol. 2013;21(12):625–33. doi: 10.1016/j.tim.2013.09.008 24238778

9. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76. doi: 10.1016/S2468-1253(16)30181-9 28404132

10. Joint United Nations Programme on HIV/AIDS. AIDS data. Geneva: Joint United Nations Programme on HIV/AIDS; 2016 [cited 2017 Jun 8]. Available from: http://www.unaids.org/sites/default/files/media_asset/2016-AIDS-data_en.pdf.

11. Mehta SH, Lucas GM, Solomon S, Srikrishnan AK, McFall AM, Dhingra N, et al. HIV care continuum among men who have sex with men and persons who inject drugs in India: barriers to successful engagement. Clin Infect Dis. 2015;61(11):1732–41. doi: 10.1093/cid/civ669 26251048

12. Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis. 2015;15(1):36–45. doi: 10.1016/S1473-3099(14)71045-X 25486851

13. Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44:174–99.

14. Heckathorn DD. Respondent driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002;49:11–34.

15. Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, et al. Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016;28(10):1312–5. doi: 10.1080/09540121.2016.1178698 27178119

16. Gwadz M, Cleland CM, Perlman DC, Hagan H, Jenness SM, Leonard NR, et al. Public health benefit of peer-referral strategies for detecting undiagnosed HIV infection among high-risk heterosexuals in New York City. J Acquir Immune Defic Syndr. 2017;74(5):499–507. doi: 10.1097/QAI.0000000000001257 28267698

17. Solomon SS, Lucas GM, Celentano DD, McFall AM, Ogburn E, Moulton LH, et al. Design of the Indian NCA study (Indian National Collaboration on AIDS): a cluster randomized trial to evaluate the effectiveness of integrated care centers to improve HIV outcomes among men who have sex with men and persons who inject drugs in India. BMC Health Serv Res. 2016;16(1):652. doi: 10.1186/s12913-016-1905-5 27842543

18. Lucas GM, Solomon SS, Srikrishnan AK, Agrawal A, Iqbal S, Laeyendecker O, et al. High HIV burden among people who inject drugs in 15 Indian cities. AIDS. 2015;29(5):619–28. doi: 10.1097/QAD.0000000000000592 25715105

19. Solomon SS, Mehta SH, Srikrishnan AK, Vasudevan CK, McFall AM, Balakrishnan P, et al. High HIV prevalence and incidence among MSM across 12 cities in India. AIDS. 2015;29(6):723–31. doi: 10.1097/QAD.0000000000000602 25849835

20. Tun W, Katzen LL, Abbott SA, Srikrishnan AK, Kelly CA, Sarna A, et al. Using a 2-stage strategy with respondent-driven sampling to recruit a hard-to-reach population for a placebo microbicide gel clinical trial in Nellore, Andhra Pradesh (India). AIDS Behav. 2015;19(2):369–79. doi: 10.1007/s10461-014-0938-1 25384905

21. Cowan FM, Davey CB, Fearon E, Mushati P, Dirawo J, Cambiano V, et al. The HIV care cascade among female sex workers in Zimbabwe: results of a population-based survey from the Sisters Antiretroviral Therapy Programme for Prevention of HIV, an Integrated Response (SAPPH-IRe) Trial. J Acquir Immune Defic Syndr. 2017;74(4):375–82. doi: 10.1097/QAI.0000000000001255 27930599

22. Aung PP, Ryan C, Bajracharya A, Pasricha N, Thein ZW, Agius PA, et al. Effectiveness of an integrated community- and clinic-based intervention on HIV testing, HIV knowledge, and sexual risk behavior of young men who have sex with men in Myanmar. J Adolesc Health. 2017;60(2S2):S45–53. doi: 10.1016/j.jadohealth.2016.09.006 28109340

23. Baral SD, Ketende S, Schwartz S, Orazulike I, Ugoh K, Peel SA, et al. Evaluating respondent-driven sampling as an implementation tool for universal coverage of antiretroviral studies among men who have sex with men living with HIV. J Acquir Immune Defic Syndr. 2015;68(Suppl 2):S107–13.

24. HIV Prevention Trials Network. HPTN 078: enhancing recruitment, linkage to care and treatment for hiv-infected men who have sex with men (MSM) in the United States. Seattle: HIV Prevention Trials Network; 2017 [cited 2017 Jun 8]. Available from: https://hptn.org/research/studies/hptn078.

25. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS ONE. 2013;8(5):e64604. doi: 10.1371/journal.pone.0064604 23741348

26. National AIDS Control Organization. Annual report 2015–16. New Delhi: National AIDS Control Organization; 2016 [cited 2017 Jun 8]. Available from: http://naco.gov.in/sites/default/files/Annual Report 2015-16.pdf.